Vaderis, Receives

Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia

Veröffentlicht: 07.08.2025 um 18:09 Uhr, prnewswire.co.uk

Vaderis Therapeutics AG Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom United States of America Canada Europe Maryland

View original content:https://www.prnewswire.co.uk/news-releases/vaderis-receives-fda-fast-track-designation-for-vad044-for-the-treatment-of-hereditary-hemorrhagic-telangiectasia-302307364.html

en | boerse | 67920898 |